*Breast Cancer Research and Treatment* **51**: 283, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

## Author index, Volume 51

Adams JB 183
Amadori D 267

Ballesta AM 109
Block CC 121
Bonadonna G 133
Bontenbal M 139
Bryant J 239
Budel V 39

Cahen P 39
Canfield VA 169
Chaboteaux C 39
Chan KK 29
Chen Y-Y 209
Cirulli V 57
Clark GM 255
Collins CA 121
Costantino J 239

Darro F 39
Decaestecker C 39
Demicheli R 133
Domanico SZ 55
Drislane FW 121

El Etreby MF 149
Emir B 239
Escriche C 109
Estapa J 109

Farrus B 109
Filella X 109
Fisher B 239
Foekens JA 139

Gasparini G 193
Geyer CE Jr 169
Goodwin DK 169
Green SJ 169
Gündüz N 239

Hamburger AW 71
Hebert JR 17
Humphrey CC 121
Hurley TG 17
Hylton H 83

Jensen RA 195
Jo J 109
Jolesz F 121

Kiosses WB 57
Kiss R 39
Klijn JGM 139

Latre ML 109
Leblond B 39
Lessor T 71
Liang Y 149
Lu C 121
Lundin C 1

Ma Y 17
Martino S 169
Melkoumian Z 83
Mertens F 1
Meyers FJ 169
Moinpour CM 169
Molina R 109
Muñoz M 109

Nogaret J-M 39

O'Sullivan J 169
Osborne CK 169,227

Page DL 195
Pahisa J 109
Pétein M 39
Peters HA 139
Peterson VA 83
Plopper GE 57
Pourrias B 39

Quaranta V 57

Rajgolikar G 29
Ramos C 39
Roberts-Thomson SJ 99

Schnitt SJ 209
Schoenlein PV 149
Schoofs A 39
Sieuwerts AM 139
Silvestrini R 267
Simpson JF 195
Snyderwine E 99
Stomper PC 121
Strobl JS 83

Talcott JA 121
Terenziani M 133

van Putten WLJ 139
Vianna A 39

Wang H-C R 29
Wen PY 121
Wenger CR 255
Wrenn RW 149

Yoo J-Y 71

Zanon G 109

*Breast Cancer Research and Treatment* **51**: 285-287, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

## Subject index, Volume 51

adrenal androgens and risk
  opposing estrogens in premenopause, activating ER in postmenopause 183-188
androgens
  *see* adrenal androgens
anticancer agents
  effect of depsipeptide FR901228 on apoptosis in breast cancer cells 29-38
antiprogestins
  additive effect of mifepristone and tamoxifen on MCF-7 apoptosis 149-168
apoptosis
  effect of anticancer agent depsipeptide FR901228 in breast cancer cells 29-38
  induced by gamma radiation and pimozide in MCF-7 cells 83-95
AU-565 human breast cancer cells
  ER-negative — additive inhibition by heregulin β1 and 17β-estradiol 71-81

Bcl-2
  downregulation in additive MCF-7 inhibition by mifepristone and tamoxifen 149-168
beer consumption
  effect on recurrence and death after diagnosis 17-28
benign breast disease
  cytogenetics compared with breast cancer 1-15
body weight
  effect on recurrence and death after diagnosis 17-28

CEA (carcinoembryonic antigen)
  and c-erbB-2 as serum markers for diagnosis and prognosis 109-119
chemotherapy
  subjective symptomatic response evaluation in paclitaxel phase II study 169-181
clinical trials
  subjective symptomatic response evaluation in paclitaxel phase II study 169-181
cytogenetics
  of benign breast lesions, compared with breast cancer 1-15

diagnosis
  histopathology and prognosis 195-208
diet
  effect on recurrence and death after diagnosis 17-28
dietary fat
  enhanced rat tumor induction by PhIP; increased β-casein and transferrin mRNAs 99-107
differential display
  decreased β-casein and transferrin mRNAs in PhIP-induced rat tumors 99-107
doxorubicin uptake
  no effect of estradiol in MCF-7 cells 139-148

endocrine therapy
  steroid receptors and response prediction 227-238
ErbB-2
  and CEA in serum for diagnosis and prognosis 109-119
estradiol
  additive inhibition with heregulin β1 of ER-negative breast cancer cell lines 71-81
estrogen receptors
  in prognosis and treatment response prediction 227-238
extracellular matrix
  roles of laminin-5 and integrins on migration of transformed breast cells 57-69

fat consumption
effect on recurrence and death after diagnosis 17-28
FR901228
anticancer depsipeptide — effect on apoptosis in breast cancer cells 29-38

growth models
estimate of extended dormancy after surgery, then rapid growth to local recurrence 133-137

heregulin β1
and 17β-estradiol — additive inhibition of ER– breast cancer cell lines 71-81
histologic grade
application in prognosis 195-208

integrins
and static adherence vs. migration of normal and transformed breast cells 57-69

karyotypes
of benign breast lesions, compared with breast cancer 1-15

laminin-5
and static adherence vs. migration of normal and transformed breast cells 57-69
local recurrence
estimate of extended dormancy after surgery, then rapid growth to local recurrence 133-137
lymphatic vessel invasion
and prognosis in tumors <1cm 209-225

MCF-7 human breast cancer cells
additive effect of mifepristone and tamoxifen on apoptosis 149-168
effect of anticancer agent depsipeptide FR901228 on apoptosis 29-38
no effect of estradiol on doxorubicin uptake and retention 139-148
radiation sensitization and apoptosis by pimozide 83-95
MDA-MB-231 human breast cancer cells
effect of anticancer agent depsipeptide FR901228 on apoptosis 29-38
metastases
oncologic, radiologic, and neurologic risk factors in suspected spinal cord compression 121-131
microinvasive carcinoma
and prognosis in tumors <1cm 209-225
mifepristone
additive effect with tamoxifen on MCF-7 apoptosis 149-168
migration of transformed vs. normal breast cells
roles of laminin-5 and integrins 57-69
MXT mouse mammary cancer model
effect of receptor-selective retinoid vs. tamoxifen 39-55

nodal status
and prognosis in tumors <1cm 209-225

obesity
effect of relative body weight on recurrence and death after diagnosis 17-28

paclitaxel
extended phase II study, including subjective symptomatic response 169-181
PhIP-induced rat mammary tumors
decreased β-casein and transferrin mRNAs by differential display vs. normal 99-107
pimozide
radiation sensitization and growth inhibition in MCF-7 cells 83-95
predictive factors
special issue 193-281
steroid receptors and hormone therapy 227-238
thymidine labelling index 267-281
progesterone receptors

radiation sensitization
in MCF-7 cells by the neuroleptic drug pimozide 83-95
rat mammary tumors (PhIP-induced)
decreased β-casein and transferrin mRNAs by differential display vs. normal 99-107
response to therapy
subjective symptomatic response evaluation in paclitaxel phase II study 169-181
retinoids
receptor-selective, vs. tamoxifen and RU-486, against breast cancer models 39-55
risk factors
adrenal androgens — a re-appraisal 183-188
RU-486
vs. receptor-selective retinoids against breast cancer models 39-55

S-phase fraction
in prognosis for ER+ node-negative breast cancer 239-253
review of prognostic study results and methodology 255-265
serum markers
c-erbB-2, CEA, and CA 15.3 in diagnosis and prognosis 109-119
sigma 2 sites
in radiation sensitization and apoptosis by pimozide 83-95
smoothing splines
to relate treatment failure with tumor characteristics 239-253
spinal cord compression
oncologic, radiologic, and neurologic risk factors in suspected cases 121-131
statistical methods
smoothing splines to relate treatment failure with tumor characteristics 239-253
steroid receptors
in prognosis and treatment response prediction 227-238

T47-D human breast cancer cells
effect of retinoids, tamoxifen, RU-486 — anchorage dependent vs. independent 39-55
tamoxifen
additive effect with the antiprogestin mifepristone on MCF-7 apoptosis 149-168
vs. receptor-selective retinoids against breast cancer models 39-55
Taxol
*see* paclitaxel
TGFβ1
involvement in additive MCF-7 inhibition by mifepristone and tamoxifen 149-168
thymidine labelling index
prognostic and predictive value 267-281
treatment response prediction
*see* predictive factors
tumor dormancy
evidence for rapid growth after extended dormancy following surgery 133-137
tumor grade
application in prognosis 195-208
tumor size
prognostic factors for tumors <1cm 209-225
tumor suppressor genes
cytogenetic evidence for chromosome 3p13-14 1-15